D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety

Bookmark and Share
Published: 14 Jun 2019
Views: 336
Prof Philippe Moreau - Chu Nantes, Nantes, France

Prof Philippe Moreau presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the part 1 results of the CASSIOPEIA study.

The addition of daratumumab increased the depth of response and the PFS with acceptable safety and the favourable benefit-risk profile supports the use of D-VTd in transplant-eligible NDMM.